Determination of formulation factors that affect oral medicines acceptability in a domiciliary paediatric population

Barriers to administering non-oral formulations in a paediatric population: A semi-structured interview study

“…A total of 280 participants consented to the FIND OUT study (Venables et al, 2015). In total, 90 118 participants were prescribed at least one non-oral formulation.…”

“…The children prescribed only oral formulations will not be discussed in this paper; these have been 122 published previously (Venables et al, 2015).…”

Choice of excipients for gelly-like pulp prepared ex tempore “on a spoon”– “placebo” and with sartans

“…for crushed tablets). However, in contrast to the widespread practice of mixing medicines with food, the ''pulp'' as an industry-verified formulation does not bring a risk of drug instability [8][9][10] . Furthermore, the product in the form of a granules is characterized by a large flexibility of dosage with regard to age 3,6,9 , as it can be scale-weight into doses suitable for a wide population of pediatric patients.…”

“…Oral powders, granules and liquids normally provide greater dosing flexibility than oral single unit dosage forms 7,8 . Powders and granules as well as crushed tablets or capsules content are taken with drinks or food for ease of swallowing 9,10 . Mixing oral powders and granules with a small amount of soft food or with a drink prior to administration is also accepted by the European Medicines Agency (EMA) and World Health Organization, on condition that information which commonly available foods are suitable for mixing with the preparation, and also list of food that should be avoided due to the instability, incompatibility or bad taste issues will be provided 3,6 .…”

O22 3D printed polyethylene oxide oral doses with innovative ‘radiator-like’ design: impact of molecular weight on mechanical and rheological properties and drug release

“…Developing medicines that are acceptable to CYP has the potential to improve treatment outcomes. 1 Acceptability has been defined as 'an overall ability of the patient and caregiver (defined as 'user') to use a medicinal product as intended'. 2 There is limited evidence for the acceptability of tablets in CYP.…”